REVVITY, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
JPMorgan raised its price target for Revvity from $110 to $155. TD Cowen also increased its target to $175 from $130. Revvity's stock has risen 60.29% year-to-date, trading at $155.08 at the time of the report.
TD Cowen raised its price target for Revvity to $175 from $130. The stock is currently trading at $155.61. Baird also recently increased its target to $164 from $144. The changes reflect updated analyst expectations for the company's performance.
Analysts made several calls on Tuesday, including Goldman Sachs lowering Netflix's price target but maintaining a buy rating, Wells Fargo upgrading Cleveland-Cliffs, and Mizuho raising AMD's price target to $705. Other notable moves include upgrades for Skyworks Solutions, Dollar General, and Prosperity Bancshares, while new coverage was initiated on companies like AvePoint, Pasqal Holdings, and Standard Nuclear.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RVTY (REVVITY, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent RVTY coverage spans financial news, market movers and technology.
In the last 30 days, RVTY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($249K). The most active reporter was Gonzales Anita, VP and CAO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade suggests upside potential for Revvity.
Analyst target raise may generate buying interest.
Positive outlook from sector tailwinds and new coverage.
Analyst initiation with a positive rating may lift the stock.
The upgrade signals stronger earnings expectations, likely prompting buying pressure.
AlphAI scores every news story that mentions RVTY with an AI model for sentiment and relevance, and aggregates insider trades from REVVITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
JPMorgan raised its price target for Revvity from $110 to $155. TD Cowen also increased its target to $175 from $130. Revvity's stock has risen 60.29% year-to-date, trading at $155.08 at the time of the report.
1 min readTD Cowen raised its price target for Revvity to $175 from $130. The stock is currently trading at $155.61. Baird also recently increased its target to $164 from $144. The changes reflect updated analyst expectations for the company's performance.
1 min readAnalysts made several calls on Tuesday, including Goldman Sachs lowering Netflix's price target but maintaining a buy rating, Wells Fargo upgrading Cleveland-Cliffs, and Mizuho raising AMD's price target to $705. Other notable moves include upgrades for Skyworks Solutions, Dollar General, and Prosperity Bancshares, while new coverage was initiated on companies like AvePoint, Pasqal Holdings, and Standard Nuclear.
3 min readWilliam Blair initiated coverage on Revvity Inc (NYSE:RVTY) with an outperform rating, expecting 4.8% 2026 growth and $7.23 2028 EPS. The stock is up 57% YTD. Q2 earnings beat estimates, with $1.41 EPS and $729.68M revenue. Analysts have mixed views on its valuation and growth prospects.
1 min readRevvity (RVTY) was upgraded to a Zacks Rank #2 (Buy) due to upward revisions in earnings estimates. The change reflects positivity about the company's earnings outlook, which could drive stock price appreciation. The Zacks rating system tracks consensus EPS estimates and has a strong track record of correlating with stock price movements.
1 min readRevvity launched the GSP T1D 3plex kit, a CE-IVDR-certified test for early type 1 diabetes detection in children. The kit uses dried blood samples and is available in Europe. The company aims to expand into child health screening and will present related services at an upcoming diabetes conference. Revvity also recently received FDA clearance for a testosterone test.
2 min readRevvity (RVTY) reported Q2FY26 results with 3% organic growth and adjusted EPS of $1.41, exceeding guidance. Diagnostics revenue rose 11% organically, while Life Sciences declined 3%. Management raised full-year guidance, citing improved market conditions and strategic reinvestments. Total revenue is projected between $2.83B and $2.86B.
2 min readSeveral biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
2 min readLeerink Partners raised its price target for Revvity to $160 from $145 and maintained an Outperform rating. The company's stock is currently trading at $142.11, with a 5-day change of -0.84% and a year-to-date change of +46.88%.
1 min readRevvity, Inc. (NYSE:RVTY) SVP Tajinder Vohra sold shares worth $1.0M at $141, reducing his holding by 38%. No insider buying occurred in the past year. Insiders own 0.4% of shares, valued at $67M. The company has 2 identified warning signs.
1 min read
